Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Staar Surgical ( (STAA) ) just unveiled an announcement.
On March 3, 2026, STAAR Surgical reported fourth quarter 2025 net sales of $57.8 million, up 18.1% year over year, driven mainly by China, while sales excluding China slipped 2.1% and quarterly adjusted EBITDA reached breakeven. Gross margin improved sharply to 75.7%, but the company still posted a quarterly net loss of $18.3 million, partly reflecting merger-termination and restructuring costs, although underlying operating expenses fell once those items were excluded.
For full-year 2025, net sales declined 23.7% to $239.4 million due to channel inventory reductions in China, even as revenue outside China grew 6.6% and gross margin held steady at 76.2%. STAAR recorded a wider annual net loss of $80.4 million and an adjusted EBITDA loss of $6.6 million, but management highlighted normalized inventories and recovering in‑market demand in China, a successful EVO+ ICL launch, and recent leadership changes and cost controls as setting a clearer path to sustainable profitability and renewed growth as a standalone company.
The most recent analyst rating on (STAA) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
Spark’s Take on STAA Stock
According to Spark, TipRanks’ AI Analyst, STAA is a Neutral.
The score is primarily held down by poor financial performance (large losses and negative operating cash flow) and a bearish technical setup (below key moving averages with negative MACD). Valuation provides limited support given the negative P/E and no dividend, while corporate events are mixed with improved governance but heightened strategic uncertainty after the terminated merger.
To see Spark’s full report on STAA stock, click here.
More about Staar Surgical
STAAR Surgical Company (Nasdaq: STAA), based in Lake Forest, California, is a global leader in phakic intraocular lenses, marketing its EVO family of Implantable Collamer Lenses for vision correction. The company focuses on lens-based refractive surgery, with a significant strategic emphasis on the large and growing myopia market, particularly in China, and has been ramping Swiss manufacturing to support key product launches.
Average Trading Volume: 1,616,096
Technical Sentiment Signal: Strong Sell
Current Market Cap: $947.6M
Find detailed analytics on STAA stock on TipRanks’ Stock Analysis page.